search
Back to results

Egg Ingestion in Adults With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Egg inclusion
Egg exclusion
Sponsored by
Griffin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Type 2 Diabetes focused on measuring Type 2 Diabetes, Egg, Glycemic Control, Insulin sensitivity, Diet quality

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • males age greater than 35 years;
  • post-menopausal females not currently on hormone replacement therapy;
  • non-smokers;
  • clinical diagnosis of Type 2 diabetes mellitus for at least 1 year but no more than 5 years;
  • 6.5% ≤ HbA1c ≤8.0% (5) BMI between 25 and 40 kg/m².

Exclusion Criteria:

  • failure to meet inclusion criteria;
  • anticipated inability to complete study protocol for any reason;
  • current eating disorder;
  • use of antihyperglycemic, lipid-lowering or antihypertensive medications unless stable on medication for at least 3 months;
  • use of glucocorticoids, antineoplastic agents, psychoactive agents, or nutraceuticals;
  • regular use of fiber supplements;
  • restricted diets (i.e., vegetarian, vegan, gluten free);
  • known allergy to eggs.

Sites / Locations

  • Yale-Griffin Prevention Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Egg inclusion

Egg exclusion

Arm Description

Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.

Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products. During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained.

Outcomes

Primary Outcome Measures

Glycemic Index
Glycated hemoglobin A1c (HbA1c) will be used to measure the average plasma glucose concentration.

Secondary Outcome Measures

Fasting glucose and insulin
Glucose and insulin will be measured at each time point. Participants will be asked to fast at least 8 hours before glucose and insulin measurement. Homeostasis Model Assessment (HOMA-IR) values will be calculated from fasting serum glucose and serum insulin levels using HOMA calculator version 2.2.1 to gauge the degree of insulin resistance.
Body Composition
Body composition will be measured using bioelectrical impedance analysis, which uses the resistance of electrical flow through the body to estimate body fat. The Tanita SC-240 Body Composition Analyzer will be used to measure body composition. The SC-240 Body Composition Analyzer measures weight and calculates body fat% and total body water% in addition to BMI.
Body Weight
Body weight will be measured during each visit. It will be measured to the nearest 0.5 pound using a balance-type medical scale. Subjects will be measured in the morning (fasting), unclothed with the exception of undergarments.
Waist Circumference
Waist circumference will be measured using the U.S. government standard protocol. It will be measured around the narrowest point between ribs and hips when viewed from the front after exhaling.
Diet Quality
To help the study team track any variation in dietary pattern over the course of the study, all participants will be asked at two time points to provide information on the foods and beverages that they consumed during a 3-day period. For each 3-day period, participants will complete three 24-hour recalls using a web-based Automated Self-Administered 24-Hour Recall (ASA24) (available from the National Cancer Institute at http://riskfactor.cancer.gov/tools/instruments/asa24/) which will guide them through the process of completing the recall data. Diet quality will be assessed using the Alternative Healthy Eating Index (AHEI). 3-day food period data will be collected at baseline, 6 weeks and 12 weeks.
Physical Activity
Physical activity will be determined by the Seven-Day Physical Activity Recall [PAR]. The PAR is one of the most widely used physical activity assessments in exercise science and epidemiological research. The popularity of this measure stems largely from its versatility and relative ease of use for research applications. The PAR provides detail regarding the duration, intensity, and volume (energy expenditure) of physical activity and can therefore be used for a variety of applications. Because it utilizes a one-week time frame, the data from the PAR is often considered representative of typical activity patterns. While it requires considerable cognitive effort by the participants, the interviewer administered version can be completed in a reasonable amount of time (~20 minutes). Variation in physical activity level will be controlled in our multivariable regression models.

Full Information

First Posted
January 29, 2014
Last Updated
November 1, 2017
Sponsor
Griffin Hospital
Collaborators
American Egg Board
search

1. Study Identification

Unique Protocol Identification Number
NCT02052037
Brief Title
Egg Ingestion in Adults With Type 2 Diabetes
Official Title
Egg Ingestion in Adults With Type 2 Diabetes: Effects on Glycemic Control, Anthropometry, Diet Quality and Cardiometabolic Status A Randomized, Controlled, Crossover Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Griffin Hospital
Collaborators
American Egg Board

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
We propose a prospective, randomized, single-blind controlled crossover study to assess the effects of daily egg inclusion versus egg exclusion, on glycemic control, anthropometric measures, and overall diet quality in adults with Type 2 diabetes.
Detailed Description
Hypothesis Inclusion of eggs in the diets of individuals with Type 2 diabetes mellitus will improve glycemic control, anthropometric measures and overall diet quality. Restriction of dietary cholesterol, and thus the avoidance or restriction of egg intake, is routinely recommended to patients at increased risk for CVD, including those with diabetes. However, the relative importance of dietary cholesterol to serum lipids and the role of egg ingestion in cardiovascular risk are increasingly suspect. Further, the exclusion of eggs from the diet may lead to increased consumption of high-glycemic carbohydrate foods of particular potential harm to individuals with diabetes. The examination of how food-specific recommendations translate into effects on other food choices and overall diet quality, and in turn health effects, is a neglected area of research. Eggs provide a complete profile of amino acids and an array of micronutrients, and are low in total fat. Although epidemiological and clinical studies largely suggest a lack of association between egg intake and harmful effects, the evidence is somewhat more ambiguous with regard to glycemic control for diabetes, or the risk for CVD among individuals with diabetes. Our own prior work shows no adverse effects of egg ingestion in healthy adults, hyperlipidemic adults, or adults with established coronary artery disease. As a satiating and protein-rich food, eggs have potential to foster calorie and weight control, and to reduce the dietary glycemic load, offering potential advantages in Type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 Diabetes, Egg, Glycemic Control, Insulin sensitivity, Diet quality

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Egg inclusion
Arm Type
Experimental
Arm Description
Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
Arm Title
Egg exclusion
Arm Type
Experimental
Arm Description
Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products. During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained.
Intervention Type
Dietary Supplement
Intervention Name(s)
Egg inclusion
Intervention Description
Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Egg exclusion
Intervention Description
Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products. During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks.
Primary Outcome Measure Information:
Title
Glycemic Index
Description
Glycated hemoglobin A1c (HbA1c) will be used to measure the average plasma glucose concentration.
Time Frame
12-weeks
Secondary Outcome Measure Information:
Title
Fasting glucose and insulin
Description
Glucose and insulin will be measured at each time point. Participants will be asked to fast at least 8 hours before glucose and insulin measurement. Homeostasis Model Assessment (HOMA-IR) values will be calculated from fasting serum glucose and serum insulin levels using HOMA calculator version 2.2.1 to gauge the degree of insulin resistance.
Time Frame
12-weeks
Title
Body Composition
Description
Body composition will be measured using bioelectrical impedance analysis, which uses the resistance of electrical flow through the body to estimate body fat. The Tanita SC-240 Body Composition Analyzer will be used to measure body composition. The SC-240 Body Composition Analyzer measures weight and calculates body fat% and total body water% in addition to BMI.
Time Frame
12- weeks
Title
Body Weight
Description
Body weight will be measured during each visit. It will be measured to the nearest 0.5 pound using a balance-type medical scale. Subjects will be measured in the morning (fasting), unclothed with the exception of undergarments.
Time Frame
12- weeks
Title
Waist Circumference
Description
Waist circumference will be measured using the U.S. government standard protocol. It will be measured around the narrowest point between ribs and hips when viewed from the front after exhaling.
Time Frame
12-weeks
Title
Diet Quality
Description
To help the study team track any variation in dietary pattern over the course of the study, all participants will be asked at two time points to provide information on the foods and beverages that they consumed during a 3-day period. For each 3-day period, participants will complete three 24-hour recalls using a web-based Automated Self-Administered 24-Hour Recall (ASA24) (available from the National Cancer Institute at http://riskfactor.cancer.gov/tools/instruments/asa24/) which will guide them through the process of completing the recall data. Diet quality will be assessed using the Alternative Healthy Eating Index (AHEI). 3-day food period data will be collected at baseline, 6 weeks and 12 weeks.
Time Frame
Baseline, 6-weeks, 12-weeks
Title
Physical Activity
Description
Physical activity will be determined by the Seven-Day Physical Activity Recall [PAR]. The PAR is one of the most widely used physical activity assessments in exercise science and epidemiological research. The popularity of this measure stems largely from its versatility and relative ease of use for research applications. The PAR provides detail regarding the duration, intensity, and volume (energy expenditure) of physical activity and can therefore be used for a variety of applications. Because it utilizes a one-week time frame, the data from the PAR is often considered representative of typical activity patterns. While it requires considerable cognitive effort by the participants, the interviewer administered version can be completed in a reasonable amount of time (~20 minutes). Variation in physical activity level will be controlled in our multivariable regression models.
Time Frame
12-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: males age greater than 35 years; post-menopausal females not currently on hormone replacement therapy; non-smokers; clinical diagnosis of Type 2 diabetes mellitus for at least 1 year but no more than 5 years; 6.5% ≤ HbA1c ≤8.0% (5) BMI between 25 and 40 kg/m². Exclusion Criteria: failure to meet inclusion criteria; anticipated inability to complete study protocol for any reason; current eating disorder; use of antihyperglycemic, lipid-lowering or antihypertensive medications unless stable on medication for at least 3 months; use of glucocorticoids, antineoplastic agents, psychoactive agents, or nutraceuticals; regular use of fiber supplements; restricted diets (i.e., vegetarian, vegan, gluten free); known allergy to eggs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David L. Katz, MPH,MD
Organizational Affiliation
Yale-Griffin Prevention Research Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Valentine Y. Njike, MPH,MD
Organizational Affiliation
Yale-Griffin Prevention Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale-Griffin Prevention Research Center
City
Derby
State/Province
Connecticut
ZIP/Postal Code
06418
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28761662
Citation
Njike VY, Annam R, Costales VC, Yarandi N, Katz DL. Which foods are displaced in the diets of adults with type 2 diabetes with the inclusion of eggs in their diets? A randomized, controlled, crossover trial. BMJ Open Diabetes Res Care. 2017 Jul 13;5(1):e000411. doi: 10.1136/bmjdrc-2017-000411. eCollection 2017.
Results Reference
derived
PubMed Identifier
28074139
Citation
Njike VY, Ayettey RG, Rajebi H, Treu JA, Katz DL. Egg ingestion in adults with type 2 diabetes: effects on glycemic control, anthropometry, and diet quality-a randomized, controlled, crossover trial. BMJ Open Diabetes Res Care. 2016 Dec 22;4(1):e000281. doi: 10.1136/bmjdrc-2016-000281. eCollection 2016.
Results Reference
derived

Learn more about this trial

Egg Ingestion in Adults With Type 2 Diabetes

We'll reach out to this number within 24 hrs